https://www.aigom.it/wp-content/uploads/2026/09/Screenshot-2026-09-08-101832.png631748Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-09-08 08:18:562026-09-08 08:18:56CLINICAL TRIAL ACADEMY: ALLA RICERCA DELLA RICETTA PERFETTA-CORSO DI FORMAZIONE IN RICERCA CLINICA 5°EDIZIONE O6-07 OTTOBRE 2026
https://www.aigom.it/wp-content/uploads/2026/09/Screenshot-2026-09-08-094824-1.png786945Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-09-08 07:49:022026-09-08 07:50:53ALLIANCE AGAINST CANCER 11TH ANNUAL MEETING-NAPLES 10-12 SETTEMBRE 2026
https://www.aigom.it/wp-content/uploads/2026/07/ART217A-1.png606400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-07-21 15:42:512026-07-21 16:16:48THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER WITH DRIVER ALTERATIONS: ASCO LIVING GUIDELINE, 2026.3.1.
https://www.aigom.it/wp-content/uploads/2026/07/art14.7-copertina.png692450Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-07-14 16:21:302026-07-14 16:21:30PREDICTING THE PROGNOSIS OF BREAST CANCER BY USING NUTRION-BASED INDEX: A SYSTEMATIC REVIEW AND META-ANALYSIS.
https://www.aigom.it/wp-content/uploads/2026/07/art7.7.png651400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-07-07 07:43:362026-07-07 07:43:36DEFINING CARDIOVASCULAR ENDPOINTS IN ONCOLOGY TRIALS: CHALLENGES AND OPPORTUNITIES: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION.
https://www.aigom.it/wp-content/uploads/2026/06/ART30.6.png645450Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-06-30 13:51:182026-06-30 13:51:18OPPORTUNISTIC SALPINGECTOMY FOR PREVENTION OF TUBO-OVARIAN CARCINOMA: THE EUROPEAN SOCIETY OF GYNAECOLOGICAL ONCOLOGY CONSENSUS STATEMENTS.
https://www.aigom.it/wp-content/uploads/2026/06/ART23.1.png714450Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-06-23 06:35:132026-06-23 06:35:13THE PATHOLOGIC RESPONSE EVALUATION AND DETECTION IN CIRCULATING TUMOR-DNA STUDY: ULTRASENSITIVE CIRCULATING TUMOR-DNA ASSESSMENT OF BREAST CANCER MINIMAL RESIDUAL DISEASE.
https://www.aigom.it/wp-content/uploads/2026/06/ART9.6.png501400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-06-09 09:50:562026-06-09 09:50:56FINAL ANALYSIS RESULTS AND PATIENT-REPORTED OUTCOMES FROM DESTINY-LUNG02-A DOSE-BLINDED, RANDOMIZED, PHASE 2 STUDY OF TRASTUZUMAB DERUXTECAN IN PATIENTS WITH HER2-MUTANT METASTATIC NSCLC
